172 related articles for article (PubMed ID: 27861143)
1. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.
Bilen MA; Hess KR; Campbell MT; Wang J; Broaddus RR; Karam JA; Ward JF; Wood CG; Choi SL; Rao P; Zhang M; Naing A; General R; Cauley DH; Lin SH; Logothetis CJ; Pisters LL; Tu SM
Oncotarget; 2016 Dec; 7(52):86280-86289. PubMed ID: 27861143
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.
Tu SM; Bilen MA; Hess KR; Broaddus RR; Kopetz S; Wei C; Pagliaro LC; Karam JA; Ward JF; Wood CG; Rao P; Tu ZH; General R; Chen AH; Nieto YL; Yeung SC; Lin SH; Logothetis CJ; Pisters LL
Cancer; 2016 Jun; 122(12):1836-43. PubMed ID: 27018785
[TBL] [Abstract][Full Text] [Related]
3. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Heterogeneity, Chemoresistance and Lymph Node Landing Zone Prognosis in Testicular Tumors Based on Histopathological Characteristics.
Singh Y; Barua SK; Singh VK; Trivedi S; Rajeev TP; Koti SR; Garg N
Ann Surg Oncol; 2024 May; 31(5):3544-3553. PubMed ID: 38381210
[TBL] [Abstract][Full Text] [Related]
5. Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors?
Beck SD; Foster RS; Bihrle R; Cheng L; Donohue JP
J Urol; 2005 Oct; 174(4 Pt 1):1287-90; discussion 1290. PubMed ID: 16145394
[TBL] [Abstract][Full Text] [Related]
6. Prediction models for the viability of pulmonary metastatic lesions after chemotherapy in nonseminomatous germ cell tumors.
Tsunezuka H; Nakamura T; Fujikawa K; Shimomura M; Okada S; Shimada J; Teramukai S; Ukimura O; Inoue M
Int J Urol; 2020 Mar; 27(3):206-212. PubMed ID: 31916319
[TBL] [Abstract][Full Text] [Related]
7. Tumors of the Testis: Morphologic Features and Molecular Alterations.
Howitt BE; Berney DM
Surg Pathol Clin; 2015 Dec; 8(4):687-716. PubMed ID: 26612222
[TBL] [Abstract][Full Text] [Related]
8. Primary mediastinal germ cell tumours with high prevalence of somatic malignancy: An experience from a single tertiary care oncology centre.
Beg A; Kumar R; Sahay A; Janu A; Joshi A; Noronha V; Prabhash K; Karimundackal G; Jiwnani S; Agarwal JP; Pramesh CS
Ann Diagn Pathol; 2021 Aug; 53():151763. PubMed ID: 34111707
[TBL] [Abstract][Full Text] [Related]
9. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
10. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
11. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
12. Histopathological and molecular features of late relapses in non-seminomas.
Mayer F; Wermann H; Albers P; Stoop H; Gillis AJ; Hartmann JT; Bokemeyer CC; Oosterhuis JW; Looijenga LH; Honecker F
BJU Int; 2011 Mar; 107(6):936-43. PubMed ID: 20955261
[TBL] [Abstract][Full Text] [Related]
13. RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors.
Mata DA; Yang SR; Ferguson DC; Liu Y; Sharma R; Benhamida JK; Al-Ahmadie HA; Chakravarty D; Solit DB; Tickoo SK; Gupta S; Arcila ME; Ladanyi M; Feldman DR; Reuter VE; Vanderbilt CM
Urology; 2020 Oct; 144():111-116. PubMed ID: 32721511
[TBL] [Abstract][Full Text] [Related]
14. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
15. Germ cell neoplasms of the testis.
Ulbright TM
Am J Surg Pathol; 1993 Nov; 17(11):1075-91. PubMed ID: 8214253
[TBL] [Abstract][Full Text] [Related]
16. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Sheinfeld J
Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
[TBL] [Abstract][Full Text] [Related]
17. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.
Balzer BL; Ulbright TM
Am J Surg Pathol; 2006 Jul; 30(7):858-65. PubMed ID: 16819328
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
20. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
